Volagidemab

Volagidemab
Monoclonal antibody
Type	?
Clinical data
Other names	REMD-477; AMG-477
Legal status
Legal status	Investigational;
Identifiers
CAS Number	1233956-13-2;
DrugBank	DB16421;
UNII	77JYS6UZ0M;

Volagidemab (development name REMD-477) is a monoclonal antibody that targets the glucagon receptor. It is developed by REMD Biotherapeutics for type 1 and type 2 diabetes. A phase II trial did not meet its primary endpoint.^[1]^[2]^[3]

References[edit]

^ Pettus, Jeremy; Reeds, Dominic; Cavaiola, Tricia S.; Boeder, Schafer; Levin, Michelle; Tobin, Garry; Cava, Edda; Thai, Dung; Shi, Jim; Yan, Hai; Bautista, Edgar; McMillan, John; Unger, Roger; Henry, Robert R.; Klein, Samuel (May 2018). "Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial". Diabetes, Obesity and Metabolism. 20 (5): 1302–1305. doi:10.1111/dom.13202. PMC 6181222. PMID 29283470.
^ Pettus, Jeremy; Boeder, Schafer C.; Christiansen, Mark P.; Denham, Douglas S.; Bailey, Timothy S.; Akturk, Halis K.; Klaff, Leslie J.; Rosenstock, Julio; Cheng, Mickie H.M.; Bode, Bruce W.; Bautista, Edgar D.; Yan, Hai; Thai, Dung; Garg, Satish K.; Klein, Samuel (1 June 2021). "236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial". Diabetes. 70 (Supplement_1). doi:10.2337/db21-236-OR. S2CID 237783919.
^ Pettus, Jeremy; Boeder, Schafer C.; Christiansen, Mark P.; Denham, Douglas S.; Bailey, Timothy S.; Akturk, Halis K.; Klaff, Leslie J.; Rosenstock, Julio; Cheng, Mickie H. M.; Bode, Bruce W.; Bautista, Edgar D.; Xu, Ren; Yan, Hai; Thai, Dung; Garg, Satish K.; Klein, Samuel (October 2022). "Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial". Nature Medicine. 28 (10): 2092–2099. doi:10.1038/s41591-022-02011-x. PMC 9872851. PMID 36192552.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Pettus, Jeremy; Reeds, Dominic; Cavaiola, Tricia S.; Boeder, Schafer; Levin, Michelle; Tobin, Garry; Cava, Edda; Thai, Dung; Shi, Jim; Yan, Hai; Bautista, Edgar; McMillan, John; Unger, Roger; Henry, Robert R.; Klein, Samuel (May 2018). "Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial". Diabetes, Obesity and Metabolism. 20 (5): 1302–1305. doi:10.1111/dom.13202. PMC 6181222. PMID 29283470.

[2] Pettus, Jeremy; Boeder, Schafer C.; Christiansen, Mark P.; Denham, Douglas S.; Bailey, Timothy S.; Akturk, Halis K.; Klaff, Leslie J.; Rosenstock, Julio; Cheng, Mickie H.M.; Bode, Bruce W.; Bautista, Edgar D.; Yan, Hai; Thai, Dung; Garg, Satish K.; Klein, Samuel (1 June 2021). "236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial". Diabetes. 70 (Supplement_1). doi:10.2337/db21-236-OR. S2CID 237783919.

[3] Pettus, Jeremy; Boeder, Schafer C.; Christiansen, Mark P.; Denham, Douglas S.; Bailey, Timothy S.; Akturk, Halis K.; Klaff, Leslie J.; Rosenstock, Julio; Cheng, Mickie H. M.; Bode, Bruce W.; Bautista, Edgar D.; Xu, Ren; Yan, Hai; Thai, Dung; Garg, Satish K.; Klein, Samuel (October 2022). "Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial". Nature Medicine. 28 (10): 2092–2099. doi:10.1038/s41591-022-02011-x. PMC 9872851. PMID 36192552.

[1]

[2]

[3]